Adult survivors of childhood or adolescent osteosarcoma require ongoing medical follow-up in order to monitor for potentially life-threatening consequences of therapy, including second cancers and anthracycline cardiotoxicity. In the future, additional knowledge of tumor biology will likely change staging methods and allow intensive therapy to be given only to those most likely to benefit from it [25]; those with less risk of relapse may require less toxic therapy and still achieve acceptable levels of survival.





Polls results
1

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
66% Article relates to my practice (2/3)
0% Article does not relate to my practice (0/3)
33% Undecided (1/3)
2

Will this article lead to more cost-effective healthcare?

33% Yes (1/3)
33% No (1/3)
33% Undecided (1/3)
3

Was this article biased? (commercial or personal)

0% Yes (0/3)
100% No (3/3)
0% Undecided (0/3)
4

What level of evidence do you think this article is?

0% Level 1 (0/3)
0% Level 2 (0/3)
66% Level 3 (2/3)
0% Level 4 (0/3)
33% Level 5 (1/3)